Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Drug: cisplatin
Drug: docetaxel
Drug: fluorouracil
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2006-07-14

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 4

Registration Number: NCT00352118

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer

Phase 3

Completed

Conditions: Rectal Neoplasms

Interventions: Drug: 5-FU and oxaliplatin
Drug: 5-FU

First Posted Date: 2006-07-06

Last Posted Date: 2016-08-01

Lead Sponsor: University of Erlangen-Nürnberg Medical School

Target Recruit Count: 1256

Registration Number: NCT00349076

Locations: 🇩🇪
Kreiskliniken Altötting-Burghausen, Altötting, Germany
🇩🇪
Krankenhaus Marienwörth, Bad Kreuznach, Germany
🇩🇪
Gesundheitszentrum St. Marien, Amberg, Germany

and more 82 locations

Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C

Phase 4

Completed

Conditions: Glaucoma

First Posted Date: 2006-06-30

Last Posted Date: 2007-12-27

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 70

Registration Number: NCT00346489

Locations: 🇺🇸
University Hospital and Outpatient Center, Indianapolis, Indiana, United States
🇺🇸
IU Eye at Carmel, Indianapolis, Indiana, United States

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Phase 1

Completed

Conditions: Lung Cancer
Colorectal Cancer

First Posted Date: 2006-06-23

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 31

Registration Number: NCT00343408

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Jewish General Hospital - Montreal, Montreal, Quebec, Canada

Docetaxel in Locally Advanced Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: Fluorouracil

First Posted Date: 2006-06-22

Last Posted Date: 2014-11-04

Lead Sponsor: Sanofi

Target Recruit Count: 59

Registration Number: NCT00343239

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: celecoxib
Drug: fluorouracil
Procedure: conventional surgery
Radiation: radiation therapy
Procedure: tumor biopsy
Other: laboratory biomarker analysis

First Posted Date: 2006-06-15

Last Posted Date: 2013-03-05

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 24

Registration Number: NCT00336960

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus, Nashville, Tennessee, United States

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Epirubicin

First Posted Date: 2006-06-14

Last Posted Date: 2012-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 273

Registration Number: NCT00336791

Locations: 🇪🇸
Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇲🇽
Centro Medico Nacional de Occidente, Guadalajara, Mexico

and more 1 locations

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Procedure: conventional surgery
Radiation: radiation therapy
Drug: oxaliplatin
Other: laboratory biomarker analysis
Genetic: DNA analysis
Genetic: polymerase chain reaction
Other: immunohistochemistry staining method

First Posted Date: 2006-06-12

Last Posted Date: 2024-10-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 248

Registration Number: NCT00335816

Locations: 🇺🇸
Cancer Care Center at John Muir Health - Concord Campus, Concord, California, United States
🇺🇸
St. Joseph Hospital Regional Cancer Center - Orange, Orange, California, United States
🇺🇸
Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States

and more 12 locations

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: docetaxel
Drug: cyclophosphamide
Drug: methotrexate
Drug: 5-fluorouracil

First Posted Date: 2006-05-29

Last Posted Date: 2017-03-28

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 300

Registration Number: NCT00331097

Locations: 🇮🇹
Azienda Ospedaliera G. Rummo, Benevento, BN, Italy
🇮🇹
Policlinico Monteluce, Sant'Andrea delle Frate, PG, Italy
🇮🇹
Università Federico II, Cattedra di Oncologia Medica, Napoli, Italy

and more 5 locations

Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer

Phase 2

Completed

Conditions: Anal Cancer

Interventions: Biological: cetuximab
Drug: cisplatin
Drug: fluorouracil
Radiation: radiation therapy

First Posted Date: 2006-05-11

Last Posted Date: 2018-06-06

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 45

Registration Number: NCT00324415

Locations: 🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy